• We studied tianeptine/arginine interaction on cortical spreading depression (CSD).
Introduction
The neurophysiological phenomenon of cortical spreading depression (CSD), first described by Aristides Leão [1] , is characterized by neuronal depolarization followed by reduction ("depression") of electrical activity resulting from chemical, mechanical, or electrical stimulation of a point of the cortex. CSD propagates slowly (with typical velocities ranging from 2 to 5 mm/min) from the site of origin to the rest of the cortical tissue. It is a reversible phenomenon, and it has been recorded in many vertebrate species [2] , including humans [3] . CSD is thought to be related to clinical disorders such as epilepsy [1] and migraine with aura [4] .
Attempts to elucidate the relationship between such diseases and CSD emphasize the role played by the serotonergic system [5] . Compelling evidence indicates that the serotonergic system participates in mechanisms of CSD propagation; for example, drugs that activate the serotonergic system reduce CSD effects [6] . Our group previously demonstrated that both the serotonin reuptake enhancer, tianeptine [7] , and the nitric oxide precursor, l-arginine [8] , facilitate CSD propagation. However, it remains unknown whether the effects of these serotonergic and nitrergic agents on CSD interact.
The effects of arginine on CSD are likely associated with nitric oxide synthesis in the brain [9] . The main mechanism of action of tianeptine, a tricyclic antidepressant, is increasing the speed of selective serotonin reuptake, especially within the neocortex [10] . Thus, it is possible that tianeptine promotes cortical hyperexcitability by diminishing brain serotonin availability.
Strong interactions between the nitrergic and serotonergic systems have been documented. Nitric oxide increases the release of serotonin [11] and inhibits serotonin reuptake in brain synaptosomes [12] . In rats, le Grand et al. [13] demonstrated that serotonin depletion induces cortical hyperexcitability and that this effect involves the nitric oxide pathway, suggesting a close relationship between nitric oxide and serotonin. In addition, serotonergic antidepressants decrease nitric oxide synthase activity in the rat hippocampus [14] .
The present study aims to answer the following question: Does tianeptine further enhance or potentiate the effects of l-arginine treatment on CSD? To address this subject, CSD electrophysiological data were obtained from the cortex of young and adult rats that were systemically treated with arginine from postnatal day 7-28, and subjected to topical tianeptine treatments.
Methods

Animals
Forty newborn female Wistar rats were used in this study. The animals were handled in accordance with the standards of the Ethics Committee for Animal Research of our university, which comply with the "Principles of Laboratory Animal Care" (NIH; Bethesda, USA). The animals were subjected to a 12/12 h light-dark cycle in which the light period began at 6:00 a.m. The animals were housed at a room temperature of 23 ± 1 • C and had free access to water and food (commercial diet, Purina LTD). Pups were assigned to two treatment groups that received by gavage either 300 mg/kg/day arginine (Sigma-Aldrich, diluted in distilled water; n = 20) or the control (water; n = 20) from postnatal days 7-28.
Cortical spreading depression electrophysiological record
For CSD recording, young (30-40 days old; n = 20) and adult (90-120 days old, n = 20) animals were intraperitoneally anesthetized with 1000 mg/kg urethane and 40 mg/kg chloralose. Rectal temperature was kept at 37 ± 1 • C using an electric heating plate positioned under the animal. A hole, measuring 2-3 mm in diameter, was drilled into the right frontal bone to apply the CSD-eliciting stimulus (2% KCl solution). Moreover, a rectangular opening (4 × 2 mm) was drilled into the parietal bone. Two recording electrodes were positioned on this parietal opening (see skull diagram in Fig. 1 ). Recording was performed using Ag-AgCl electrodes against a common reference electrode placed over the nasal Electrocorticogram (E) and slow potential change (P) recorded during cortical spreading depression (CSD), in young and adult rats that were previously treated (from postnatal days 7-28) by gavage (one gavage/day) with 300 mg/kg/d of l-arginine or distilled water. During the recording session, tianeptine solution (TNP; 10 mg/ml) was topically applied at 2 recording sites onto intact dura mater for 10 min. Horizontal bars indicate the 1-min period of stimulation with 2% KCl necessary to elicit CSD. The vertical bars equal −10 mV and −1 mV, respectively for the P and E recordings (negativity is upwards). The sites of KCl application and reference electrode (R) are indicated in the skull diagram, which also shows recording sites 1 and 2 (from which the corresponding traces marked on the left were recorded).
bones. CSD was induced at 20-min intervals by applying a cotton ball (1-2 mm diameter) soaked in 2% KCl to the frontal cortical surface for one minute. The electrocorticogram and slow potential shift accompanying the CSD were recorded for a 4 h period. CSD propagation velocity was calculated from the distance between the two recording electrodes and the time it took the CSD to travel this distance. The amplitude (in mV) and duration (in s) of the CSD slow potential shift were also calculated from the beginning of the negative shift to recovery to baseline.
Topical application of tianeptine
Tianeptine solution (Servier; 10 mg/ml) was topically applied to the intact dura mater over the exposed parietal cortex, according to a previously described protocol [7] . Briefly, after an 80-min baseline recording (during which 4 CSD episodes were elicited), tianeptine was applied to intact dura mater. Ten minutes after the onset of a CSD episode, tianeptine treatment was conducted for 10 min. Following the 10-min tianeptine application, treated cortex was wiped with a small piece of cotton and CSD was immediately elicited. The tianeptine application and CSD elicitation sequence was repeated three times at 20-min intervals. During this period, CSD velocity as well as CSD slow potential shift amplitude and duration were measured every 20 min. After tianeptine treatment was terminated, three CSD episodes were subsequently elicited and recorded at 20 min intervals to document the post-tianeptine recovery of CSD features. CSD-propagation velocities recorded after topical tianeptine treatment were compared to values obtained during baseline recording for each animal. Cortical spreading depression (CSD) propagation velocity (mean ± standard deviation) in young and adult rats that were previously treated (from postnatal days 7-28) by gavage (one gavage/day) with 300 mg/kg/d of l-arginine or distilled water. During the recording session, tianeptine solution (TNP; 10 mg/ml) was topically applied at 2 recording sites onto intact dura mater for 10 min. This procedure enhanced CSD velocity in comparison with baseline velocity. After TNP application (post-TNP period), CSD velocity tended to return to baseline values. * = adult < young values; black dot symbols = l-arginine > water values; # = TNP > baseline and post-TNP values (P < 0.05, ANOVA plus Tukey test).
Statistics
To analyze the effects of l-arginine, CSD features were compared between groups by using ANOVA with gavage treatment (water and arginine) and age (young and adult) as factors, followed by a post hoc test (Tukey), where indicated. A paired t-test was used to analyze the effects of topical tianeptine application by comparing CSD features before and after treatment in each animal. Differences were considered significant when P ≤ 0.05.
Results
Cortical spreading depression features under baseline conditions
Frontal cortical surface stimulation for 1 min with 2% KCl (approximately 270 mM) usually elicited a single CSD wave that propagated without interruption and was recorded at each parietal recording site. During CSD recording, the appearance of the slow potential change confirmed the presence of CSD after each KCl stimulation event (baseline recordings of Fig. 1 ; see the recording sites in the skull diagram).
Age and cortical spreading depression features
In agreement with previous findings [15] , the present comparative data for young and adult rats indicates that CSD propagation inversely correlates with age. Baseline CSD velocity in young rats (3.85 ± 0.07 mm/min) was significantly higher than that of adult rats (3.53 ± 0.23 mm/min; p < 0.05) (left part of Fig. 2 , baseline bars). After confirming the age-effect on CSD propagation velocity, we measured the amplitude and duration of the negative CSD slow potential shift. We found that the CSD slow potential shift amplitude and duration of young rats were respectively higher and shorter (11.8 ± 1.7 mV and 69.4 ± 8.8 s) than those of adults (9.8 ± 1.0 mV and 77.9 ± 6.6 s, p < 0.05; left part of Fig. 3 ).
Arginine and cortical spreading depression features
In the present study, we confirmed that systemic treatment with 300 mg/kg/d arginine early in development facilitates CSD propagation [8] (Fig. 2) . CSD velocity (in mm/min) in argininetreated groups was 4.50 ± 0.27 and 3.91 ± 0.09 for young and adult rats, respectively. These values were significantly higher Fig. 3 . Amplitude (mV) and duration (s) of the negative cortical spreading depression (CSD) slow potential shift in young and adult rats that were previously treated (from postnatal days 7-28) by gavage (one gavage/day) with 300 mg/kg/d of larginine or distilled water. During the recording session, tianeptine solution (TNP; 10 mg/ml) was topically applied at 2 recording sites onto intact dura mater for 10 min. Data are mean ± standard deviation. * = young value different from adult value; # = l-arginine group different from water-treated group. For each age-group, values with different lower-case letters are significantly different (p < 0.05; ANOVA followed by the Tukey test).
than corresponding water-treated controls (3.85 ± 0.07 (young) and 3.53 ± 0.23 (adult); p < 0.05). In addition, we measured the amplitude and duration of the negative CSD slow potential shift. We found that arginine treatment was associated with higher amplitudes (13.7 ± 1.2 mV and 13.9 ± 1.9 mV for young and adult rats, respectively), compared to controls (amplitudes for young and adult control rats were 11.8 ± 1.7 mV and 9.8 ± 1.0 mV, respectively; p < 0.05). Regarding CSD duration, no significant difference was observed (71.1 ± 5.0 s and 73.8 ± 11.7 s for young and adult arginine-treated rats, respectively), compared to controls (durations for young and adult control rats were 69.4 ± 8.8 s and 77.9 ± 6.6 s, respectively). Data on CSD amplitude and duration are shown in Fig. 3. 
Tianeptine and cortical spreading depression features
For each animal, comparisons of CSD velocity, amplitude and duration pre-and post-topical tianeptine treatment revealed a facilitating effect of tianeptine on CSD. In water-treated controls, tianeptine significantly increased (p < 0.05) CSD velocity from 3.85 ± 0.07 mm/min to 4.28 ± 0.14 mm/min in young rats (representing an increase of 11%), and from 3.53 ± 0.23 mm/min to 4.34 ± 0.29 mm/min in adults (a 23% increase) (Fig. 2) . During the post-tianeptine period (following termination of tianeptine treatment), the CSD velocity of young and adult control rats returned to 3.96 ± 0.17 mm/min and 3.93 ± 0.24 mm/min, respectively. The amplitude of the slow, direct current (DC)-shift of CSD increased from a baseline value of 11.8 ± 1.7 mV in young rats and 9.8 ± 1.0 mV in adult rats to 12.7 ± 2.8 mV (young rats) and 12.7 ± 1.2 mV (adult rats). Following the termination of tianeptine treatment, the final amplitudes were 14.7 ± 2.4 mV in young rats and 14.1 ± 1.4 mV in adult rats. The duration of the DC-shift of CSD decreased from a baseline value of 69.4 ± 8.8 s in young rats and 77.9 ± 6.6 s in adult rats to 58.7 ± 5.8 s (young rats) and 61.6 ± 6.3 s (adult rats). Following the termination of tianeptine treatment, the final duration was 53.8 ± 7.6 s in young rats and 54.1 ± 6.1 s in adult rats (Fig. 3) .
In arginine-treated young rats, topical tianeptine enhanced CSD velocity from a basal value of 4.50 ± 0.27 mm/min to 5.13 ± 0.36 mm/min (p < 0.05). In the post-tianeptine period (following termination of tianeptine treatment), CSD velocity returned to 4.75 ± 0.34 mm/min. In adult rats, CSD velocities for the baseline period, tianeptine period and post-tianeptine period were 3.91 ± 0.09 mm/min, 4.54 ± 0.32 mm/min and 4.11 ± 0.32 mm/min, respectively (Fig. 2) . The amplitude of the DC-shift of CSD increased from a baseline value of 13.7 ± 1.2 mV (young rats) and 13.9 ± 1.9 mV (adult rats) to 16.0 ± 2.1 mV and 16.3 ± 2.2 mV in young and adult rats, respectively. Following the termination of tianeptine treatment, three additional measurements revealed amplitude values of 16.1 ± 2.7 mV (young rats) and 17.4 ± 4.3 mV (adult rats). The duration of the DC-shift of CSD after tianeptine decreased from a baseline value of 71.1 ± 4.9 s (young rats) and 73.8 ± 11.7 s (adult rats) to 52.2 ± 10.7 s (young rats) and 61.7 ± 8.5 s (adult rats). During the post-tianeptine period (three CSD episodes after terminating tianeptine treatment), the durations were 46.7 ± 5.6 s (young rats) and 58.4 ± 10.6 s (adult rats) (Fig. 3) .
Discussion
In this study, we investigated whether two CSD-facilitating conditions-systemic treatment with arginine and topical treatment with tianeptine-would interact in the cerebral cortex of young and adult rats to influence CSD features. Since the mammalian brain develops early in life [16] , we systemically administered arginine to rats during the lactation period using a previously reported protocol [8] . Our data suggest that the CSDfacilitating actions of tianeptine and l-arginine do not interact.
By comparing young and adult rats (Fig. 2) , we confirmed previous findings suggesting an inverse correlation between age and CSD propagation [15, 17] . Although the present age-dependent CSD effects can be explained by distinct mechanisms, we postulate that increased oxidative stress [18] and cerebral blood flow impairment [19] are two likely processes involved in CSD impairment in older animals.
The administration of 300 mg/kg/day arginine during brain development influenced CSD parameters (i.e., increased velocity and amplitude, and decreased duration) in treated rats, leading to CSD acceleration compared to control animals. This effect was observed both in young and adult animals (Figs. 2 and 3) , indicating an absence of age effects in the animals studied. Furthermore, the persistence of CSD acceleration in adult rats indicates that arginine has a long-lasting effect on CSD. Considering compelling evidence for the promotion of nitric oxide synthesis by arginine [20, 21] , we postulate that our findings can be accounted for by a nitric oxide-based mechanism. It is probable that prolonged treatment (over 21 days) with 300 mg/kg/d arginine enhanced neuronal nitric oxide synthesis and consequently increased cerebral blood vessel reactivity, influencing CSD [22] . Furthermore, we have previously demonstrated that arginine treatment early in life was associated with increased density of dendrite varicosities and of dendrite branching frequency of NADPH-containing neurons, in adult life, suggesting a lasting, plastic response of the developing brain to that treatment [23] . Our data suggest that changes in neuronal excitability [24] and ionic homeostasis [25] following arginine treatment may have contributed to modulation of CSD. In contrast, endothelial nitric oxide production directly influences the CSD threshold [26] . Future studies determining cortical nitric oxide levels in rats systemically treated with arginine are required to test our hypothesis.
Tianeptine reduces serotonin availability in several brain areas, including the neocortex [10] . In the rat, we previously demonstrated that systemic and topically applied serotonin-enhancing drugs impair CSD [6] , whereas systemic and topical tianeptine enhances it [7] . Furthermore, acute administration of tryptophan, the precursor for serotonin synthesis, impairs CSD propagation [27] . Taken together, these data indicate that CSD is modulated by serotonin-dependent processes, and they suggest an inverse correlation between cortical serotonin activity and CSD propagation. Brain serotonin activity can inhibit free radical production, as was recently demonstrated for the 5-hydroxy-tryptamine 1a (5HT1a) receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) [28] . Free radicals may increase in brain tissue when physiological antioxidant mechanisms fail to counteract them [29] . Interestingly, this scenario facilitates CSD [30] . Furthermore, antioxidant substances may impair CSD propagation [31] .
We previously demonstrated that topical application of tianeptine accelerates CSD more effectively than systemic administration of tianeptine [7] ; however, in humans, the use of topical tianeptine is less relevant. Differences in the effectiveness of systemic or topical application for other serotonergic drugs have been described [6] . Importantly, in agreement with previous observations, our experiments demonstrated that the CSD velocity effects of topical tianeptine were reversible (Fig. 2) . Although we cannot exclude the participation of indirect mechanisms, topical cortical application of tianeptine replicated the effect of systemic application, [7] suggesting a cortically based mechanism for tianeptine's action. Therefore, we suggest that the effects of tianeptine on CSD observed in the present study were associated with brain serotonin availability. Since serotonin exhibits marked inhibitory action on the central nervous system, it is reasonable to consider serotonergic drugs as candidates for the treatment of migraines, epilepsy and other excitatory neurological disorders [32] .
In conclusion, the present data confirm two previous findings: first, CSD propagation inversely correlates with age, and second, tianeptine and l-arginine accelerate CSD. Moreover, the present study demonstrates, for the first time, that the CSD-accelerating actions of these drugs do not interact.
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